Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
INTRATHECAL THERAPY CONSENSUS Introduction: The use of intrathecal (IT) infusion of analgesic medications to treat patients with chronic refractory pain has increased since its inception in the 1980s, and the need for clinical research in IT therapy is ongoing. The Polyanalgesic Consensus Conference (PACC) panel of experts convened in 2000, 2003, and 2007 to make recommendations on the rational use of IT analgesics based on preclinical and clinical literature and clinical experiences. Methods: The PACC panel convened again in 2011 to update the standard of care for IT therapies to reï¬ect current knowledge gleaned from literature and clinical experience. A thorough literature search was performed, and information from this search was provided to panel members. Analysis of published literature was coupled with the clinical experience of panel members to form recommendations regarding the use of IT analgesics to treat chronic pain. Results: After a review of literature published from 2007 to 2011 and discussions of clinical experience, the panel created updated algorithms for the rational use of IT medications for the treatment of neuropathic pain and nociceptive pain. Conclusions: The advent of new algorithmic tracks for neuropathic and nociceptive pain is an important step in improving patient care. The panel encourages continued research and development, including the development of new drugs, devices, and safety recommendations to improve the care of patients with chronic pain. Keywords: Chronic pain, consensus, intrathecal Conï¬ict of Interest: Timothy R. Deer, MD: consulting (Medtronic, Spinal Modulation, St. Jude, Medasys, Bioness, Vertos). Robert Levy, MD, PhD: consulting (Medtronic and Codman & Shurtleï¬). Joshua Prager, MD: honoraria (Medtronic, Eli Lily, Qutenza). Allen Burton, MD: consulting (Medtronic, BSCIS, Stryker), speaking (Azur, Cadence, Cephalon, NeurogesX, Pricara, Pï¬zer), stockholder (Vapogenix). Eric Buchser, MD: consulting (Medtronic). David Caraway, MD, PhD: consulting (Medtronic, Spinal Modulation, MedSys, Codman). Sudhir Diwan, MD: speaking (Neurotherm, BSCI). Eric Grigsby, MD: clinical research (Alfred Mann Foundation, Medtronic, NeurogesX, Spinal Restoration), speaking (Azur Pharma), consulting (Medtronic, St. Jude Medical, Spinal Modulation, Vertos, Xalud), stock options (Spinal Modulation, Spinal Restoration, Vertos, Xalud). Marilyn Jacobs, PhD: consulting (Medtronic). Philip Kim, MD: consulting (Medtronic, Biotronik, Stryker, Azur). Krishna Kumar, MD: consulting and research (Medtronic, Boston Scientiï¬c). Michael Leong, MD: advisor (Covidien). Liong Liem, MD: grant (Spinal Modulation). Gladstone McDowell, MD: speaking (Azur), consulting (Medtronic, Mysys). Nagy Mekhail, MD, PhD: spe(Endo Pharmaceutical), research (Baylis, Inc., Vertos). Richard Rauck, MD: research (Medtronic, Medasys, Azur, Codman, Al Mann Foundation), consulting (Medtronic, Medasys, Azur), data and safety monitoring board membership (Medtronic, Al Mann Foundation). Michael Saulino, MD, PhD: speaking (Medtronic, Azur), research (Medtronic). Lisa Stearns, MD: research (Medtronic, Insys Therapeutics, Vertos), consulting (Medtronic). Mark Wallace, MD: research and consulting (Medtronic). K. Dean Willis, MD: speaking (Boston Scientiï¬c, Medtronic, St. Jude Medical), Implantable Systems Performance Registry participant (Medtronic), advisory committee (Boston Scientiï¬c). William Witt, MD: consulting (Medtronic), speaking (Cadence, Pï¬zer, Medtronic). José De Andrés, MD, PhD; Michael Erdek, MD; Marc Huntoon, MD, PhD; Sunil J. Panchal, MD; Peter Staats, MD; Michael Stanton-Hicks, MD; B. Todd Sitzman, MD; Michael Cousins, MD: nothing to disclose; and Tony Yaksh, PhD: consulting (Vertex, Adynxx, Solace, Neuroadjuvants, Trevana), research (Adynxx, Johnson & Johnson, Xenome, Torrey Pines, Third Rock Ventures, Advanced Targeting Systems, Nektar Pharma, Endo Pharmaceuticals, Sage Rx, Solstice, Epigen). INTRODUCTION www.neuromodulationjournal.com METHODS A broad literature search was conducted to identify preclinical and clinical data on IT therapy published from January 15, 2007, through March 1, 2011. MEDLINE®, BioMed Central®, Current Contents Connect®, Embase, International Pharmaceutical Abstracts®, and Web of Science® data bases were searched for publications on a range of medications that are either currently in use or potentially useful for the IT treatment of chronic pain. Search terms included intrathecal, intraspinal, morphine, fentanyl, sufentanil, methadone, adenosine, hydromorphone, meperidine, gabapentin, baclofen, ketorolac, midazolam, neostigmine, octreotide, ziconotide, ropivacaine, dexmedetomidine, clonidine, bupivacaine, and lidocaine. These searches yielded 391 articles, which were examined for relevance to the IT treatment of chronic pain. Google was also used to search for recent relevant © 2012 International Neuromodulation Society Neuromodulation 2012; 15: 436â466 437 The use of intraspinal (intrathecal [IT]) infusion of analgesic medications to treat patients with chronic refractory pain has increased since its inception in the 1980s, and the need for clinical research in IT therapy is ongoing. Thus far, research has not kept pace with the growing need for innovative pain management; therefore, a consensus opinion is needed to clarify the current research and address deï¬ciencies in the data. The Polyanalgesic Consensus Conference (PACC) panel ï¬rst convened in 2000 to address the research gaps and review the existing data (1). This expert panel is composed of physicians and other clinicians in the ï¬eld of IT therapy. The panel developed an IT drug selection algorithm on the basis of best evidence and expert opinion and prepared supplemental reports that included a literature review, documentation of results from a survey of peers regarding IT therapy, and projections for future directions in the ï¬eld of IT therapy. The PACC panel reconvened in 2003 (2) and 2007 (3) to evaluate the most recent literature and to update the algorithm for intraspinal drug selection. In 2011, to formulate consensus opinions on critical issues involving IT therapy and identify areas for future research in the ï¬eld, the PACC panel again convened, with objec- tives of modifying and updating the IT drug selection algorithm by reviewing previous PACC guidelines including literature published before January 14, 2007; preclinical and clinical data on IT therapy published from January 15, 2007, through March 1, 2011; and results of a peer survey.